EMA Withdrawn: Sepioglin (pioglitazone hydrochloride) — Vaia S.A.

View source ↗

Summary

Europen EMA withdrawn status for Sepioglin (pioglitazone hydrochloride) by Vaia S.A., originally for type 2 diabetes, with withdrawal decision dated 06/06/2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Sepioglin (pioglitazone hydrochloride)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Vaia S.A.. Decision date: 06/06/2013